$オキュジェン (OCGN.US)$ 1. U.S. Phase 3 Bridging Study: OCGN sub...

1. U.S. Phase 3 Bridging Study:

OCGN submitted an IND application to FDA on October 27, 2021, and FDA issued a Clinical Hold to OCGN on November 26, 2021. Currently, WE are waiting for the response from OCGN to FDA. The OCGN will receive a full response from the FDA on or after December 26, 2021. FDA will proceed with approval within 30 days of receiving OCGN's response.